Benzinga's Volume Movers

shares climbed 59.08 percent to $26.90. The volume of Five Prime Therapeutics shares traded was 2774 percent higher than normal. Five Prime Therapeutics announced a worldwide license, collaboration agreement on CSF1R antibody program with

.

shares moved up 7.23 percent to $20.91. The volume of Zafgen traded was 339 percent higher than normal. Zafgen shares have surged 8.82 percent over the past 52 weeks, while the S&P 500 index has gained 7.06 percent in the same period.

shares rose 6.60 percent to $25.67. The volume of Cellectis shares traded was 323 percent higher than normal. Cellectis' trailing-twelve-month revenue is $37.92 million.

surged 7.27 percent to $65.20. The volume of Clayton Williams Energy shares traded was 313 percent higher than normal. Clayton Williams Energy confirmed that it is reviewing strategic alternatives for the company.